Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma.

Anti-cancer peptides (ACPs) are small cationic and hydrophobic peptides that are more toxic to cancer cells than normal cells. ACPs kill cancer cells by causing irreparable membrane damage and cell lysis, or by inducing apoptosis. Direct-acting ACPs do not bind to a unique receptor, but are rather attracted to several different molecules on the surface of cancer cells. Here we report that an amidated wasp venom peptide, Mastoparan, exhibited potent anti-cancer activities toward leukemia (IC50~8-9.2μM), myeloma (IC50~11μM), and breast cancer cells (IC50~20-24μM), including multidrug resistant and slow growing cancer cells. Importantly, the potency and mechanism of cancer cell killing was related to the amidation of the C-terminal carboxyl group. Mastoparan was less toxic to normal cells than it was to cancer cells (e.g., IC50 to PBMC=48μM). Mastoparan killed cancer cells by a lytic mechanism. Moreover, Mastoparan enhanced etoposide-induced cell death in vitro. Our data also suggest that Mastoparan and gemcitabine work synergistically in a mouse model of mammary carcinoma. Collectively, these data demonstrate that Mastoparan is a broad-spectrum, direct-acting ACP that warrants additional study as a new therapeutic agent for the treatment of various cancers.

[1]  R. Hancock,et al.  Synthetic Cationic Peptide IDR-1002 Provides Protection against Bacterial Infections through Chemokine Induction and Enhanced Leukocyte Recruitment , 2010, The Journal of Immunology.

[2]  B. Sveinbjørnsson,et al.  Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide , 2010, Cancer Immunology, Immunotherapy.

[3]  J. Aerts,et al.  Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells , 2014, Oncoimmunology.

[4]  D. S. McVey,et al.  F peptide . proline-arginine-rich neutrophil antimicrobial ( PR-26 ) derived from PR-39 , a Antibacterial activity of a synthetic peptide , 1995 .

[5]  D. Hoskin,et al.  Studies on anticancer activities of antimicrobial peptides. , 2008, Biochimica et biophysica acta.

[6]  C. Leuschner,et al.  Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo , 2007, Molecular and Cellular Endocrinology.

[7]  S. Batra,et al.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells , 2010, Oncogene.

[8]  B. Bay,et al.  Targeting heparan sulfate proteoglycans in breast cancer treatment. , 2008, Recent patents on anti-cancer drug discovery.

[9]  H. Vogel,et al.  Mechanism of action of puroindoline derived tryptophan-rich antimicrobial peptides. , 2013, Biochimica et biophysica acta.

[10]  N. C. Price,et al.  How to study proteins by circular dichroism. , 2005, Biochimica et biophysica acta.

[11]  B. Ames.  ASSAY OF INORGANIC PHOSPHATE, TOTAL PHOSPHATE AND PHOSPHATASE , 1966 .

[12]  D. Hoskin,et al.  Pleurocidin-family cationic antimicrobial peptides are cytolytic for breast carcinoma cells and prevent growth of tumor xenografts , 2011, Breast Cancer Research.

[13]  Chandra Sekhar Ravuri,et al.  Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315 , 2014, Cancer Immunology, Immunotherapy.

[14]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[15]  H. Bear,et al.  Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. , 2009, International immunopharmacology.

[16]  C. Bucana,et al.  Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. , 1991, Cancer research.

[17]  K. Pasqualoto,et al.  Mastoparan induces apoptosis in B16F10-Nex2 melanoma cells via the intrinsic mitochondrial pathway and displays antitumor activity in vivo , 2015, Peptides.

[18]  K. Gelmon,et al.  In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. , 2000, Anti-cancer drug design.

[19]  P. Emmelot,et al.  Increased sialic acid density in surface glycoprotein of transformed and malignant cells--a general phenomenon? , 1973, Cancer research.

[20]  David M. Conrad,et al.  Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts , 2013, Leukemia & lymphoma.

[21]  D. Hoskin,et al.  The Application of Cationic Antimicrobial Peptides in Cancer Treatment: Laboratory Investigations and Clinical Potential , 2010 .

[22]  N. Fujii,et al.  An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. , 1996, Biochemistry.

[23]  E. Giralt,et al.  Three Valuable Peptides from Bee and Wasp Venoms for Therapeutic and Biotechnological Use: Melittin, Apamin and Mastoparan , 2015, Toxins.

[24]  M. Palma,et al.  The effects of the C-terminal amidation of mastoparans on their biological actions and interactions with membrane-mimetic systems. , 2014, Biochimica et biophysica acta.

[25]  Paavo Honkakoski,et al.  Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.